Johnson & Johnson (JNJ) : On Monday, The money flowed into the Johnson & Johnson (JNJ) stock with an uptick to downtick ratio was recorded at 2.73. Transactions worth $178.45 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $65.26 million. The total money flow into the stock was $113.2 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $109.32 million of block transactions on upticks. The total money flow in block trades was $109.32 million. In terms of price action, Johnson & Johnson (JNJ) traded down $0.55 during the session at $123.22. Compared to the previous days closing, the stock was down only by -0.44%. For the week, the stock is -0.82%, over previous weeks closing.
Johnson & Johnson has lost 1.08% in the last five trading days and dropped 0.56% in the last 4 weeks. Johnson & Johnson is up 7.64% in the last 3-month period. Year-to-Date the stock performance stands at 20.79%.
Johnson & Johnson (NYSE:JNJ): The stock opened at $123.12 on Monday but the bulls could not build on the opening and the stock topped out at $123.27 for the day. The stock traded down to $122.28 during the day, due to lack of any buying support eventually closed down at $122.31 with a loss of -0.74% for the day. The stock had closed at $123.22 on the previous day. The total traded volume was 6,469,495 shares.
In a related news,The officer (Exec VP, Finance; CFO) of Johnson & Johnson, Caruso Dominic J sold 41,146 shares at $125.01 on July 26, 2016. The Insider selling transaction had a total value worth of $5,143,661. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.